公司资料
Travere Therapeutics 股价、新闻与催化剂
- 股票代码:
- TVTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
65.22 USD (-0.75%)
收盘价
最后更新: 2026年8月24日
3.99B USD
市值
股价为何变动
As of Aug 24, 2026, TVTX closed down 0.75% at $65.22. No new same-company headline was identified in the current news window.
公司概览
业务概览
Travere Therapeutics is a rare-disease company with a focus on kidney and hepatology programs. Its business combines commercial execution with pipeline development in hard-to-treat diseases.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Travere sits in specialty biopharma.
商业模式特征
The model is driven by product adoption, label expansion, and development in additional rare disease settings.
生物医药行业定位
Travere is a specialty-rare-disease name whose stock can move on both commercial traction and pipeline progress.
未来催化剂
- Travere's catalysts are FILSPARI execution in IgA nephropathy and any FSGS or label-expansion step that widens the renal franchise. The company improves when the nephrology story keeps compounding.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。